FIBROGEN INC - COMMON

FibroGen Reports Third Quarter 2024 Financial Results

12 Nov 2024 16:05:02 By Nasdaq GlobeNewswire

FibroGen to Report Third Quarter 2024 Financial Results

04 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 16:05:02 By Nasdaq GlobeNewswire

FibroGen to Report Second Quarter 2024 Financial Results

30 Jul 2024 16:07:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update

30 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024

18 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

03 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

03 Jun 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting

23 May 2024 17:05:00 By Nasdaq GlobeNewswire

FibroGen to Participate in Upcoming Investor Conferences

07 May 2024 07:00:01 By Nasdaq GlobeNewswire

FibroGen Reports First Quarter 2024 Financial Results

06 May 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen to Report First Quarter 2024 Financial Results

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting

24 Apr 2024 16:02:00 By Nasdaq GlobeNewswire

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

02 Apr 2024 17:46:47 By Nasdaq GlobeNewswire

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

26 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

26 Feb 2024 16:06:00 By Nasdaq GlobeNewswire

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

26 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire